Johnson & Johnson announced FDA approval for an updated label on TREMFYA (guselkumab), highlighting its ability to inhibit structural joint damage progression in adults with active psoriatic arthritis (PsA). This update is based on positive 24-week Phase 3b APEX study results showing that TREMFYA not only reduces joint symptoms but also significantly slows irreversible joint damage, making it the only IL-23 inhibitor with this proven effect. The drug offers a treatment option that controls symptoms and protects joints without new safety concerns. This label change supports TREMFYA as a first-line therapy for patients with active PsA at risk of joint damage, addressing both symptom relief and long-term joint preservation.
Johnson & Johnson announced that their drug combination RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGF...
Johnson & Johnson announced positive Phase 3 results from the MajesTEC-9 study, showing TECVAYLI (teclistamab-cqyv) significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients treated as early as s...
